Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group

Seminars in Oncology

Volumn 36, Issue 2, 2009, Pages 170-180

  Tewari, Krishnansu S ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; TOPOTECAN; VASCULOTROPIN ANTIBODY; VINBLASTINE; VIRUS VACCINE;

ADVANCED CANCER; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEPSIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; UTERINE CERVIX CANCER; VACCINATION; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS VACCINES; PLATINUM COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 62949142263     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.12.008     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Monk B.J., Tewari K.S., and Kow W.J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 27 (2007) 2952-2965
3. Tewari K.S., and Monk B.J. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 7 (2005) 419-434
4. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., and Roman L.D. Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study (2008) Abstract #45. Presented at: 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL
5. Sill M.W., Monk B.J., McMeekin D.S., Cohn D., Ramondetta L., Boardman, et al. A randomized phase III trial of four cisplatin (cis) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study (2008) Late-breaking Abstract. Presented at: Annual Meeting of the American Society of Clinical Oncology; Chicago, IL
6. Rose P.G., Blessing J.A., Gershenson D.M., and McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 17 (1999) 2676-2680
7. Moore D.H., Blessing J.A., McQuellon R.P., Thaler H.T., Cella D., Benda J., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22 (2004) 3113-3119
8. Long III H.J., Cross W.G., Wieand H.S., Webb M.J., Mailliard J.A., Kugler J.W., et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 57 (1995) 235-239
9. Fiorica J., Holloway R., Ndubisi B., Orr J., Grendys E., Boothby R., et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 85 (2002) 89-94
10. Long III H.J., Bundy B.N., Grendys E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23 (2005) 4626-4633
11. Monk B.J., Huang H.Q., Cella D., and Long III H.J. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23 (2005) 4617-4625
12. Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donehower R.C., et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88 (1996) 734-741
13. Omura G.A., Blessing J.A., Vaccarello L., Berman M.L., Clarke-Pearson D.L., Mutch D.G., et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15 (1997) 165-171
14. Bloss J.D., Blessing J.A., Behrens B.C., Mannel R.S., Rader J.S., Sood A.K., et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 20 (2002) 1832-1837
15. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., and Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 14 (1996) 792-795
16. Moore D.H., Tian C., Monk B.J., Long H.J., and Omura G. Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: a multivariate analysis of three Gynecologic Oncology Group trials. Abstract no. 5534. J Clin Oncol ASCO Annual Meeting Proceedings Part 1 25 (2007) 18S
17. JCOG0505. Trial of cisplatin plus paclitaxel versus carboplatin plus paclitaxel regimens for stage IVB, perisistent, or recurrent cervical cancer. (R. Kitagawa and T. Kamura study chairs). Available at: www.clinicaltrials.gov.
18. Symonds R., Davidson S., Chan S., Reed N., McMahon T., and Paul J. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. Abstract no. 5548. J Clin Oncol ASCO Annual Meeting Proceedings Part 1 25 (2007) 18S
19. Bahadori H.R., Green M.R., and Catapano C.V. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 48 (2001) 188-196
20. Tiersten A.D., Selleck M.J., Hershman D.L., Smith D., Resnik E.E., Troxel A.B., et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 92 (2004) 635-638
21. West W., Birch R., Schnell F., Hainsworth J., Tongol J., and Campos L. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. Oncology 8 (2003) 76-82
22. Stathopoulos G.P., Rigatos S.K., Christodoulou C., Malamos N.A., Deliyiannis F., Stathopoulos J.G., et al. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 54 (2004) 259-264
23. Stathopoulos G.P., Malamos N.A., Aravantinos G., Rigatos S., Christodoulou C., Stathopoulos J., et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 60 (2007) 123-126
24. Homesley H.D., Benigno B., Williams J., and Vaccarello L. A phase I study of weekly topotecan and paclitaxel in previously treated ovarian carcinoma patients. Gynecol Oncol 87 (2002) 171-177
25. A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan to those of cisplatin and topotecan for treatment of patients with recurrent or persistent cervical cancer. AGO protocol IFG-01-0106 (F. Thiel study chair). www.ago-online.org.
26. Kudelka A.P., Verschraegen C.F., and Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 338 (1998) 991-992
27. Kudelka A.P., Levy T., Verschraegen C.F., Edwards C.L., Piamsomboon S., Termrungruanglert W., et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3 (1997) 1501-1505
28. Cooper R.A., Wilks D.P., Logue J.P., Davidson S.E., Hunter R.D., Roberts S.A., and West C.M. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 4 (1998) 2795-00
29. Kim K.J., Li B., Winer J., Armanini M., Gillet N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
30. Luo J.C., Toyoda M., and Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58 (1998) 2594-2600
31. Lyseng-Williamson K.A., and Robinson D.M. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. Biodrugs 20 (2006) 193-195
32. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
33. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (EGOC) study E3200. Abstract no. 169a. J Clin Oncol ASCO Annual Meetings Proceedings 23 (2007) 16S
34. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
35. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
36. Miller K.D., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
37. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endoetherlial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
38. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.L. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 5165-5171
39. GOG 218. A phase III trial of carboplatin and paclitaxel polus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (NSC #704865, IND #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, stage III or IV, epithelial ovarian or primary peritoneal cancer. (R.A. Burger study chair). www.gog.org.
40. ICON-7. A randomized, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. (T. Perren study chair). www.icon7trial.org.
41. Wright J.D., Viviano D., Powell M.A., Gibb R.K., Mutch D.G., Grigsby P.W., and Rader J.S. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103 (2006) 489-493
42. Hung C.-F., Ma B., Monie A., Tsen S.-W., and Wu T.-C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 8 (2008) 421-439
43. Hung C.-F., Wu T.C., Monie A., and Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev 222 (2008) 43-69
44. Mahdavi A., and Monk B.J. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10 (2005) 528-538
45. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 (1996) 1532-1537
46. Ressing M.E., van Driel W.J., Brandr R.M., Kenter G.G., de Jong J.H., Bauknecht T., et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23 (2000) 255-266
47. van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., et al. Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35 (1999) 946-952
48. Steller M.A., Gurski K.J., Mutakami M., Daniel R.W., Shah K.V., Celis E., et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lapidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4 (1998) 2103-2109
49. Santin A.D., Bellone S., Gokden M., Cannon M.J., and Parham G.P. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metasatic cervical cancer. N Engl J Med 346 (2002) 1752-1753
50. Santin A.D., Bellone S., Palmieri M., Ravaggi A., Romani C., Tassi R., et al. HPV 16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 100 (2006) 469-478